SRR819534
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.505
- INTERFERON_ALPHA_RESPONSE+0.497
- INFLAMMATORY_RESPONSE+0.478
- IL6_JAK_STAT3_SIGNALING+0.474
- INTERFERON_GAMMA_RESPONSE+0.444
- TNFA_SIGNALING_VIA_NFKB+0.436
- ALLOGRAFT_REJECTION+0.417
- COAGULATION+0.416
- IL2_STAT5_SIGNALING+0.414
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.392
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.577
- DNA_REPAIR-0.406
- HEDGEHOG_SIGNALING-0.324
- MYC_TARGETS_V2-0.314
- NOTCH_SIGNALING-0.260
- MYC_TARGETS_V1-0.228
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.225
- ADIPOGENESIS-0.216
- PANCREAS_BETA_CELLS-0.194
- E2F_TARGETS-0.181
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1441701 | GTEX | — | 0.979 |
| 2 | SRR1387989 | GTEX | — | 0.929 |
| 3 | SRR615731 | GTEX | — | 0.923 |
| 4 | SRR1319816 | GTEX | — | 0.919 |
| 5 | SRR1468403 | GTEX | — | 0.918 |
| 6 | SRR1079168 | GTEX | — | 0.914 |
| 7 | SRR1464411 | GTEX | — | 0.911 |
| 8 | SRR1093773 | GTEX | — | 0.909 |
| 9 | SRR1368856 | GTEX | — | 0.901 |
| 10 | MDT-AP-0363 | Med | Medulloblastoma | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.505 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.497 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.478 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.474 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.444 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.436 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.417 | Idelalisib | — uncovered |
| COAGULATION | 0.416 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.414 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.392 | Inavolisib | — uncovered |
| COMPLEMENT | 0.358 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.357 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.343 | Inavolisib | — uncovered |
| APOPTOSIS | 0.335 | Idelalisib | — uncovered |
| MYOGENESIS | 0.235 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.187 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.184 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.177 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.168 | Remibrutinib | — uncovered |